Effect of pigment epithelium-derived factor on prostaglandin E2 receptors (EP2/EP4) in glucocorticoid-induced osteoporosis in rats
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Zerrin Kutlu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Ataturk University, Erzurum 25240, Turkey. Hauptthemen laut MEDLINE: Eye Proteins, Serpins, Receptors, Prostaglandin E, EP2 Subtype, Osteoporosis. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Presidency of the Turkish Institutes of Health.
Abstract (Originalsprache)
Objectives
This study investigated the effects of pigment epithelium-derived factor (PEDF) on bone homeostasis in a glucocorticoid-induced osteoporosis (GIOP) rat model, focusing on prostaglandin E2 receptors EP2 and EP4.
Methods
Male Sprague–Dawley rats were divided into six groups. Dexamethasone (DEX, 1 mg/kg) was administered intramuscularly twice weekly for 90 days to induce osteoporosis. PEDF (50, 100, 200 mg/kg) was then given subcutaneously for 30 days. Bone mineral density (BMD) and bone morphology were assessed by computed tomography. Bone turnover markers—C-terminal telopeptide of type I collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRAP-5b), and bone-specific alkaline phosphatase—as well as EP2/EP4 mRNA expressions were evaluated using qRT-PCR. Key findings Immunohistochemical analysis was performed for ALP, osteopontin, osteocalcin, and VEGFR1. PEDF partially mitigated DEX-induced weight loss and dose-dependently restored BMD. Histopathological analyses showed improved bone architecture in all PEDF-treated groups. PEDF increased bone formation markers, reduced bone resorption markers, and upregulated EP2/EP4 expression.
Conclusion
These findings indicate that PEDF exerts protective effects against GIOP and may modulate bone metabolism through EP2/EP4 signalling pathways. PEDF shows promise as a potential therapeutic agent for preventing bone loss in GIOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Ataturk University, Erzurum 25240, Turkey.
- Department of Internal Medical Sciences, Division of Medical Pharmacology, Ataturk University Faculty of Medicine, Erzurum 25240, Turkey.
- Department of Internal Medical Sciences, Division of Medical Radiology, Ataturk University Faculty of Medicine, Erzurum 25240, Turkey.
- Department of Basic Medical Sciences, Division of Histology and Embrology, Kafkas University Faculty of Medicine, Kafkas 36100, Turkey.
- Department of Internal Medical Sciences, Division of Nuclear Medicine, Ataturk University Faculty of Medicine, Erzurum 25240, Turkey.
- Department of Pharmacy Services, Atatürk University Hınıs Vocational School, Erzurum 25240, Turkey.
ORCID-Profile: Zerrin Kutlu, Zekai Halici, Fatih Alper, Erdem Toktay, Adem Maman, Hamza Halici, Zafer Bayraktutan, Ahmet Yalcin
Förderung
- Presidency of the Turkish Institutes of Health
Zitieren
APA
Kutlu, Z., Halici, Z., Alper, F., Toktay, E., Maman, A., Halici, H., Bayraktutan, Z., & Yalcin, A. (2026). Effect of pigment epithelium-derived factor on prostaglandin E2 receptors (EP2/EP4) in glucocorticoid-induced osteoporosis in rats. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf102
Vancouver
Kutlu Z, Halici Z, Alper F, Toktay E, Maman A, Halici H, et al. Effect of pigment epithelium-derived factor on prostaglandin E2 receptors (EP2/EP4) in glucocorticoid-induced osteoporosis in rats. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf102
BibTeX
@article{Kutlu2026,
author = {Kutlu, Zerrin and Halici, Zekai and Alper, Fatih and Toktay, Erdem and Maman, Adem and Halici, Hamza and Bayraktutan, Zafer and Yalcin, Ahmet},
title = {Effect of pigment epithelium-derived factor on prostaglandin E2 receptors (EP2/EP4) in glucocorticoid-induced osteoporosis in rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf102}
}
EUVIMED